Efficacy or atrial flutter >2 d flecainide (83±11 to QRS widening more was not and w/o appropriate conversion 86±12 msec). common w/ flecainide effective at safety of anticoagulants, body 24/25 (96%) than propafenone converting AF IV weight >100 kg vs. 8/14 (57%) (p<0.001) or atrial flutter propafenone, w/in 1 hr (2 p<0.05. mg/kg 1/8 (13%) per 10 atrial flutter w/ min) vs. flecainide 2/5 (40%) (2 atrial flutter mg/kg propafenone, per 10 p=NS min) vs. Overall verapamil 10 mg 1/20 (5%) in 1 min.in pts w/ AF or flutt Roberts Clinical 115 pts Assessed N/A 18 y NYHA class III, IV, The median N/A N/A N/A Observational SA time to HR AF or atrial flutter w/ HF, surgery, AMI time to study 1993 control w/ ventricular rates ≥ 120 ventricular (186) and cost digoxin BPM rate control of (i.e., resting digoxin ventricular at rate <100 bpm, HR in decrease in AF and ventricular atrial rate of >20%, flutter in or sinus rhythm) was , 11.6 h from the first dose of digoxin for study at all evaluable 18 pts (n = 105) and 9.5 h for those only centers receiving digoxin (n = 64). Before ventricular rate control, the mean ±SD dose of
Efficacy and safety of IV (2 mg/kg per 10 min) vs. (2 mg/kg per 10 min) vs. 10 mg in 1 min.in pts w/ AF or flutt or atrial flutter >2 d w/o appropriate anticoagulants, body weight >100 kg flecainide conversion 24/25 (96%) vs. 8/14 (57%) propafenone, p<0.05. 1/8 (13%) atrial flutter w/ flecainide 2/5 (40%) atrial flutter propafenone, p=NS Overall verapamil 1/20 (5%) (83±11 to 86±12 msec). QRS widening more common w/ flecainide than propafenone (p<0.001) was not effective at converting AF or atrial flutter w/in 1 hr Roberts SA 1993 (186) Clinical and cost of digoxin at HR in AF and atrial flutter in , study at 18 centers 115 pts Assessed time to HR control w/ digoxin N/A 18 y AF or atrial flutter w/ ventricular rates ≥ 120 BPM NYHA class III, IV, HF, surgery, AMI The median time to ventricular rate control (i.e., resting ventricular rate <100 bpm, decrease in ventricular rate of >20%, or sinus rhythm) was 11.6 h from the first dose of digoxin for all evaluable pts (n = 105) and 9.5 h for those only receiving digoxin (n = 64). Before ventricular rate control, the mean ±SD dose of N/A N/A N/A Observational study
2015_SVT_Evidence_Tables_Data_Supplement.docx